Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
University Hospital Muenster |
---|---|
Information provided by: | University Hospital Muenster |
ClinicalTrials.gov Identifier: | NCT00111371 |
This study aims to determine whether levodopa, in combination with a high frequency training of (grammatical) rules, is effective in boosting learning success in healthy subjects and whether this kind of training in combination with levodopa improves reading and spelling abilities of patients with dyslexia.
Condition | Intervention | Phase |
---|---|---|
Dyslexia |
Drug: Levodopa |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Dopaminergic Enhancement of Learning and Memory (LL_001, Project on Dyslexia) |
Estimated Enrollment: | 100 |
Study Start Date: | January 2005 |
Estimated Study Completion Date: | October 2007 |
Prior work by our group shows that d-amphetamine and the dopamine precursor levodopa markedly improve word learning success in healthy subjects. In this randomized, placebo-controlled, double-blind trial, we probe whether daily administration of levodopa, coupled with a training of grammatical rules, improves the training success in healthy adults as compared to placebo administration. In the second step of this study, patients with dyslexia will be trained with the identical protocol. We postulate that the combination of intensive training in language rules and levodopa improves the reading, writing, and spelling abilities of patients with dyslexia.
Ages Eligible for Study: | 18 Years to 35 Years |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contact: Stefan Knecht, MD | +49-251-83 ext 48195 | knecht@uni-muenster.de |
Germany, North-Rhine Westphalia | |
Dept. of Neurology, University Hospital of Muenster | Recruiting |
Muenster, North-Rhine Westphalia, Germany, 48129 | |
Contact: Stefan Knecht, Prof. Dr. +49-251-83 ext 48195 knecht@uni-muenster.de | |
Principal Investigator: Stefan Knecht, M.D. |
Principal Investigator: | Stefan Knecht, Prof. Dr. | Dept. of Neurology, Universityclinic of Muenster |
Study ID Numbers: | LL-001; Project on Dyslexia |
Study First Received: | May 19, 2005 |
Last Updated: | April 18, 2007 |
ClinicalTrials.gov Identifier: | NCT00111371 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
artificial grammar learning dyslexia healthy subjects levodopa |
drug treatment intervention |
Signs and Symptoms Levodopa Dopamine Mental Disorders Mental Disorders Diagnosed in Childhood Neurologic Manifestations |
Language Disorders Dyslexia Healthy Learning Disorders Neurobehavioral Manifestations Communication Disorders |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Anti-Dyskinesia Agents Therapeutic Uses Physiological Effects of Drugs |
Nervous System Diseases Antiparkinson Agents Dopamine Agents Central Nervous System Agents Pharmacologic Actions |